Skip to content
ABOUT
AUTHOR GUIDELINES
AUTHORS/EDITORS
SUBSCRIPTIONS
CONTACT US
MY ACCOUNT
Facebook
X
LinkedIn
Instagram
Search
×
HOME
PSYCH. BULLETIN
LATEST ISSUE
BLACK BOOK OF DOSING & MONITORING
RATING SCALES
LICENSING INFORMATION
RESOURCES
PSYCHOTROPICS A-Z
PSYCHOPHARMACOLOGY 101
NEWS
Patricia R. Houck, MSH: An Intent-to-Treat Method for Enhancing Analysis of Clinical Trials with Rescue Medication: A Mixed-Model Approach
1
x
$
30.00
VOL 2 No. 1 Full Issue - January 2000
1
x
$
20.00
Gregor E. Berger, MD, FMH Psych (CH): Incipient Neurovulnerability and Neuroprotection in Early Psychosis
1
x
$
30.00
Our Current Understanding of Genetic Alterations in Colorectal Cancer, and Implications for Clinical Use
1
x
$
0.00
VOL 3 No. 4 Full Issue - April 2001
1
x
$
20.00
Boadie W. Dunlop - Exercise for Depression: Efficacy, Safety and Clinical Trial Implications
1
x
$
30.00
VOL 2 No. 10 Full Issue - October 2000
1
x
$
20.00
Desvenlafaxine and Venlafaxine Exert Minimal In Vitro Inhibition of Human Cytochrome P450 and P-Glycoprotein Activities
1
x
$
30.00
Carlos A. Zarate, MD: Modulators of the Glutamatergic System: Implications for the Development of Improved Therapeutics in Mood Disorders
1
x
$
30.00
View Cart
Checkout
Home
jorge-quiroz
“Carlos A. Zarate, MD: Modulators of the Glutamatergic System: Implications for the Development of Improved Therapeutics in Mood Disorders” has been added to your cart.
View cart
Sort by
Date
Sort by
Name
Sort by
Price
Sort by
Date
Sort by
Popularity
Show
20 Products
Show
20 Products
Show
40 Products
Show
60 Products
Carlos A. Zarate, MD: Modulators of the Glutamatergic System: Implications for the Development of Improved Therapeutics in Mood Disorders
$
30.00
Add to cart
Details
Page load link
Go to Top
